Business

Zydus Cadila gets USFDA nod to market generic tension headache tablets

The company has received final approval to market Butalbital, Acetaminophen and Caffeine tablets in strengths of 50mg/325mg/40 mg, Zydus Cadila said in a statement.

From our online archive

NEW DELHI: Drug firm Zydus Cadila on Saturday said it has received final approval from the US health regulator to market generic Butalbital, Acetaminophen and Caffeine combination tablets to treat symptoms of tension headaches.

The company has received final approval from the United States Food and Drug Administration (USFDA) to market Butalbital, Acetaminophen and Caffeine tablets in strengths of 50mg/325mg/40 mg, Zydus Cadila said in a statement.

The drug will be manufactured at Nesher Pharma's manufacturing facility at St.Louis in the US, it added.

This combination medication is used to treat symptom complex of tension (or muscle contraction) headaches, Zydus Cadila said.

The group now has 294 approvals and has filed over 390 abbreviated new drug applications (ANDAs) since the commencement of the filing process, it added.

Trump says US forces will 'finish the job' soon in first prime-time speech since starting Iran war

April 16-18 special session coming to add Lok Sabha seats for women quota

7.4-magnitude earthquake off Indonesia kills one, tsunami warning lifted

West Asia conflict: PM reviews supply chains, price stability, diversification for LPG and LNG in CCS meeting

Amazon's cloud computing facility in Bahrain hit in Iranian strike, reports Financial Times

SCROLL FOR NEXT